---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-117669"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:48:39.380235+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioXcel posts Q3 net loss $50.5M, aligns with FDA on Phase 3 for agitation in Alzheimer's dementia

## Summary
- Q3 net loss $50.5M vs $41.8M YoY; IGALMI net revenue ~$341k; cash $90M, funds through mid-2024.
- FDA alignment for Phase 3 trial of BXCL501 (60 mcg) for Alzheimer's agitation in at-home setting; ~100 patients, 4 weeks.
- SERENITY III program plans Phase 3 trial with 120 mcg dose (approved IGALMI dose) for at-home agitation in bipolar/schizophrenia.
- Binding term sheet with Oaktree and QIA to amend financing; potential access to more capital, adjusted revenue covenants.
- OnkosXcel reports positive Phase 2 overall survival for BXCL701 in prostate cancer; evaluating strategic options.

## SEC filing metadata
- accession: 0001104659-23-117669
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465923117669/0001104659-23-117669-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465923117669/tm2330471d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-117669
- JSON: https://secwatch.observer/filing/0001104659-23-117669.json
- Plain text: https://secwatch.observer/filing/0001104659-23-117669.txt

## Key facts
- Earnings Releases
  BioXcel Therapeutics, Inc. reported third quarter ended Sept. 30, 2023 results: revenue approximately $341,000, net income $50.5 million.
  - Period: third quarter ended Sept. 30, 2023
  - Revenue: approximately $341,000
  - Net income: $50.5 million
  - Result: reported results
  source text: OnkosXcel Therapeutics, including potential financing, strategic partnership, or M&A. 2 Third Quarter 2023 Financial Results Net Revenue: Net revenue of IGALMI was approximately $341,000 for the quarter. Research and Development (R&D) Expenses: R&D expenses were $19.6 million for the third quarter of 2023, compared to $22.1 million for the same period in 2022. The
  evidence_url: https://www.sec.gov/Archives/edgar/data/1720893/000110465923117669/0001104659-23-117669-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.